In 2024, the biotech industry is poised for a boom, with top Jefferies analyst predicting a surge following the Bristol Meyers-Karuna deal. Bolt Biotherapeutics Inc. (BOLT) stands out as a stock to watch, with potential to be worth over $100 billion upon FDA approval. Stay tuned for exciting developments in this rapidly growing sector.